| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 15.13% | JP Morgan | → $14 | Reinstates | → Neutral |
| 10/31/2023 | 80.92% | Stifel | $20 → $22 | Maintains | Buy |
| 10/31/2023 | 146.71% | HC Wainwright & Co. | $25 → $30 | Maintains | Buy |
| 10/31/2023 | — | JonesTrading | Upgrades | Hold → Buy | |
| 10/30/2023 | 89.14% | Piper Sandler | $18 → $23 | Upgrades | Neutral → Overweight |
| 08/10/2023 | 105.59% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/10/2023 | 64.47% | Stifel | $14 → $20 | Upgrades | Hold → Buy |
| 06/05/2023 | 89.14% | JMP Securities | → $23 | Reiterates | → Market Outperform |
| 05/04/2023 | 89.14% | JMP Securities | → $23 | Reiterates | → Market Outperform |
| 03/15/2023 | 89.14% | JMP Securities | → $23 | Reiterates | → Market Outperform |
| 02/08/2023 | 105.59% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/08/2023 | 146.71% | SVB Leerink | → $30 | Reiterates | → Outperform |
| 02/07/2023 | 146.71% | SVB Leerink | $28 → $30 | Maintains | Outperform |
| 01/25/2023 | 146.71% | Cowen & Co. | $25 → $30 | Maintains | Outperform |
| 01/06/2023 | — | JonesTrading | Upgrades | Sell → Hold | |
| 01/04/2023 | 130.26% | SVB Leerink | $25 → $28 | Maintains | Outperform |
| 01/04/2023 | -25.99% | Barclays | $8 → $9 | Maintains | Underweight |
| 01/04/2023 | 80.92% | Guggenheim | → $22 | Upgrades | Neutral → Buy |
| 09/27/2022 | 48.03% | Stifel | $11 → $18 | Maintains | Hold |
| 09/12/2022 | 105.59% | SVB Leerink | $21 → $25 | Maintains | Outperform |
| 09/12/2022 | 105.59% | HC Wainwright & Co. | $20 → $25 | Maintains | Buy |
| 08/29/2022 | 105.59% | Cowen & Co. | → $25 | Initiates Coverage On | → Outperform |
| 08/05/2022 | 72.7% | SVB Leerink | $15 → $21 | Maintains | Outperform |
| 08/05/2022 | 64.47% | HC Wainwright & Co. | $15 → $20 | Maintains | Buy |
| 08/05/2022 | 89.14% | JMP Securities | → $23 | Upgrades | Market Perform → Market Outperform |
| 02/28/2022 | -50.66% | Barclays | $11 → $6 | Downgrades | Equal-Weight → Underweight |
| 12/01/2021 | 23.36% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 11/08/2021 | -17.76% | Truist Securities | $65 → $10 | Downgrades | Buy → Hold |
| 11/08/2021 | -1.32% | Canaccord Genuity | → $12 | Downgrades | Buy → Hold |
| 11/08/2021 | 105.59% | HC Wainwright & Co. | $70 → $25 | Maintains | Buy |
| 11/08/2021 | -9.54% | Barclays | $50 → $11 | Downgrades | Overweight → Equal-Weight |
| 11/08/2021 | — | Stifel | Downgrades | Buy → Hold | |
| 11/05/2021 | -17.76% | Truist Securities | $65 → $10 | Downgrades | Buy → Hold |
| 11/05/2021 | 426.32% | JMP Securities | $70 → $64 | Maintains | Market Outperform |
| 08/04/2021 | 475.66% | HC Wainwright & Co. | $75 → $70 | Maintains | Buy |
| 05/05/2021 | 516.78% | HC Wainwright & Co. | $80 → $75 | Maintains | Buy |
| 03/31/2021 | 541.45% | Credit Suisse | → $78 | Initiates Coverage On | → Outperform |
| 02/10/2021 | 475.66% | Barclays | $85 → $70 | Maintains | Overweight |
| 02/10/2021 | 475.66% | SVB Leerink | → $70 | Upgrades | Market Perform → Outperform |
| 12/03/2020 | 516.78% | Stifel | → $75 | Initiates Coverage On | → Buy |
| 11/12/2020 | 475.66% | SVB Leerink | $58 → $70 | Maintains | Market Perform |
| 09/14/2020 | 376.97% | SVB Leerink | $54 → $58 | Maintains | Market Perform |
| 08/05/2020 | 344.08% | SVB Leerink | $55 → $54 | Maintains | Market Perform |
| 05/18/2020 | 648.36% | SunTrust Robinson Humphrey | $82 → $91 | Maintains | Buy |
| 05/07/2020 | 393.42% | Nomura | $84 → $60 | Downgrades | Buy → Neutral |
| 05/07/2020 | 393.42% | Nomura | $84 → $60 | Downgrades | Buy → Neutral |
| 05/06/2020 | 302.96% | JP Morgan | $50 → $49 | Maintains | Overweight |
| 05/06/2020 | 557.89% | HC Wainwright & Co. | $60 → $80 | Reiterates | → Buy |
| 04/29/2020 | 574.34% | SunTrust Robinson Humphrey | $77 → $82 | Maintains | Buy |
| 04/29/2020 | 352.3% | SVB Leerink | $50 → $55 | Maintains | Market Perform |
| 03/04/2020 | 475.66% | Barclays | → $70 | Initiates Coverage On | → Overweight |
| 01/22/2020 | 590.79% | Nomura | $57 → $84 | Maintains | Buy |
| 01/13/2020 | 533.22% | SunTrust Robinson Humphrey | → $77 | Initiates Coverage On | → Buy |
| 11/05/2019 | 344.08% | JMP Securities | $45 → $54 | Maintains | Market Outperform |
| 10/29/2019 | — | SVB Leerink | Upgrades | Underperform → Market Perform | |
| 10/03/2019 | 393.42% | HC Wainwright & Co. | → $60 | Initiates Coverage On | → Buy |
| 09/30/2019 | 286.51% | Jefferies | → $47 | Initiates Coverage On | → Buy |
| 08/14/2019 | 352.3% | Cantor Fitzgerald | $43 → $55 | Maintains | Overweight |
| 08/14/2019 | 434.54% | Canaccord Genuity | $50 → $65 | Reiterates | → Buy |
| 07/18/2019 | 245.39% | Deutsche Bank | → $42 | Initiates Coverage On | → Buy |
| 03/15/2019 | 311.18% | Canaccord Genuity | $55 → $50 | Maintains | Buy |
What is the target price for Deciphera Pharmaceuticals (DCPH)?
The latest price target for Deciphera Pharmaceuticals (NASDAQ: DCPH) was reported by JP Morgan on November 20, 2023. The analyst firm set a price target for $14.00 expecting DCPH to rise to within 12 months (a possible 15.13% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Deciphera Pharmaceuticals (DCPH)?
The latest analyst rating for Deciphera Pharmaceuticals (NASDAQ: DCPH) was provided by JP Morgan, and Deciphera Pharmaceuticals their neutral rating.
When is the next analyst rating going to be posted or updated for Deciphera Pharmaceuticals (DCPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Deciphera Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Deciphera Pharmaceuticals was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Deciphera Pharmaceuticals (DCPH) correct?
While ratings are subjective and will change, the latest Deciphera Pharmaceuticals (DCPH) rating was a with a price target of $0.00 to $14.00. The current price Deciphera Pharmaceuticals (DCPH) is trading at is $12.16, which is within the analyst's predicted range.